14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends

Bertolaccini, Maria Laura; Amengual, Olga; Andréoli, Laura; Atsumi, Tatsuya; Chighizola, Cecilia Beatrice; Forastiero, Ricardo; Groot, Philip de; Lakos, Gabriella; Lambert, Marc; Meroni, Pier Luigi; Ortel, Thomas L.; Petri, Michelle; Rahman, Anisur; Roubey, Robert; Sciascia, Savino; Snyder, Melissa R.; Tebo, Anne E.; Tincani, Anǵela; Willis, Rohan

doi:10.1016/j.autrev.2014.05.001

Cited by 236 publications

(165 citation statements)

References 98 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…These antibodies have been reported in up to 70% of patients with systemic lupus erythematosus (SLE) and in those with primary APS [8]. The reports on the prevalence of IgA aCL are extremely variable ranging from 0% to nearly 50% [9]. Altogether, twelve studies showed an association between IgA aCL and certain clinical features related to APS, however fifteen studies failed to find any relationship between the presence of IgA aCL and clinical signs of APS (review in [9]).…”

Section: Introductionmentioning

confidence: 99%

“…There is also added controversy in the literature regarding the meaning of elevated IgA anti-β2GPI and recently Tebo et al [10] also emphasized the variability in the performance characteristics of commercial kits for the detection of IgA anti-β2GPI. The majority of published papers have highlighted the value of IgA anti-β2GPI in the diagnosis of APS [9]. Thrombosis, particularly arterial thrombosis [6,11,12] is frequently found associated with IgA anti-β2GPI, although the simultaneous presences of other isotypes makes interpretation difficult.…”

Section: Introductionmentioning

confidence: 99%

“…The reports on the prevalence of IgA aCL are extremely variable ranging from 0% to nearly 50% [9]. Altogether, twelve studies showed an association between IgA aCL and certain clinical features related to APS, however fifteen studies failed to find any relationship between the presence of IgA aCL and clinical signs of APS (review in [9]). Studies investigating the diagnostic applicability and added value of IgA aCL show a general weakness, since elevated levels of IgA aCL are often accompanied with positive IgG and/or IgM aCL making it difficult to understand the single role of elevated IgA aCL.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Prevalence and Clinical Significance of Iga Anti-Phosphatidylserine/ Prothrombin Antibodies in Systemic Autoimmune Diseases

Å1⁄2igon¹,

AmbroÅ3⁄4iÄ²,

Mali³

et al. 2017

Immunome Res

View full text Add to dashboard Cite

Objective: Studies on antiphospholipid antibodies have mainly focused on the IgG and IgM isotypes, with only a few investigating the pathogenic significance of IgA antiphospholipid antibodies. Positive IgA anticardiolipin (aCL) and IgA anti-β2 glycoprotein I (anti-β2GPI) were reported to be predominantly associated with other antiphospholipid antibodies, making it difficult to understand the role of IgA alone. Recently, antibodies against phosphatidylserine/ prothrombin (aPS/PT) IgG and IgM have been indicated as a potential marker for antiphospholipid syndrome (APS). Our previous study reported that IgG and IgM aPS/PT showed highest association with lupus anticoagulant (LA) activity of all tested antiphospholipid antibodies, while no studies to date have investigated possible clinical benefits of IgA aPS/PT. In this study, we determined the prevalence of IgA aPS/PT in patients with systemic autoimmune diseases and evaluated their clinical association to thrombosis and obstetric complications.Methods: 254 patients with systemic autoimmune diseases were screened for LA, aCL, anti-β2GPI and aPS/PT (for IgG, IgM, IgA isotypes).Results: An overall prevalence of 63/254 (25%) was found for IgA aPS/PT in our cohort of patients. IgA aPS/PT were statistically significantly associated to LA activity and to both arterial and venous thrombosis, however no association was found to obstetric complications. Median levels of IgA aPS/PT were significantly higher in APS patients than in the non-APS patient control group comprising systemic lupus erythematosus, rheumatoid arthritis and Sjogren's syndrome patients. Conclusion:Although IgA aPS/PT were predominantly associated with other antiphospholipid antibodies this study first confirmed their presence in APS patient samples and also showed a clear association of IgA aPS/PT to thrombosis and LA activity.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Prevalence and Clinical Significance of Iga Anti-Phosphatidylserine/ Prothrombin Antibodies in Systemic Autoimmune Diseases

Å1⁄2igon¹,

AmbroÅ3⁄4iÄ²,

Mali³

et al. 2017

Immunome Res

View full text Add to dashboard Cite

show abstract

“…Antiphospholipid antibody tests that are not part of the updated Sapporo Classification Criteria, e.g., antiphosphatidylserine prothrombin or antibodies directed against domain I of the aβ 2 GPI, may be more specific for APS diagnosis and predict incident thrombotic events more accurately (18) than criteria aPL tests (19). However, their use in clinical practice is limited because of the lack of standardization and the fact that they have been mostly utilized for research purposes.…”

mentioning

confidence: 99%

“…These new classification criteria now include the IgA isotype of aCL and aβ 2 GPI, which has not been part of the revised American College of Rheumatology SLE Classification Criteria (22). However, the association between the IgA isotype and aPL-related clinical events remains controversial (23); the Laboratory Trends and Diagnostics Task Force of the 14 th International Congress on aPL recently concluded that low-quality evidence exists to include the IgA isotype as part of the APS Classification Criteria (particularly, given the fact that these isotypes are usually associated with other aPL, making it difficult to understand the role of IgA alone) (19).…”

mentioning

confidence: 99%

Untitled

2016

Eur J Rheumatol

View full text Add to dashboard Cite

Antiphospholipid Antibodies

Gupta

Johnson

Nagalla

2017

JAMA

View full text Add to dashboard Cite

A 39-year-old man with a history of ischemic stroke 10 years ago presented after 1 day of right calf swelling and shortness of breath. He reported no trauma, surgery, recent prolonged mobility limitation, or family history of thrombosis. His only medication was aspirin, 81 mg daily. On examination, his heart rate was 106/min, respiratory rate was 28/min, and swelling of the right calf was noted. A heparin drip was initiated for suspected pulmonary embolism, which was confirmed with computed tomography pulmonary angiography. Routine laboratory values were unremarkable. Warfarin was administered for longterm anticoagulation. Given the unprovoked thrombotic events at a young age, a hypercoagulable state was suspected, and testing for the antiphospholipid syndrome was performed. Two days later, results revealed elevated titers of anticardiolipin and anti-β 2 glycoprotein I antibodies and negative lupus anticoagulant screening assays (Table 1). Answer B.Results should be repeated in 12 weeks to confirm diagnosis of antiphospholipid syndrome.

show abstract

14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends

Cited by 236 publications

References 98 publications

The Prevalence and Clinical Significance of Iga Anti-Phosphatidylserine/ Prothrombin Antibodies in Systemic Autoimmune Diseases

The Prevalence and Clinical Significance of Iga Anti-Phosphatidylserine/ Prothrombin Antibodies in Systemic Autoimmune Diseases

Untitled

Antiphospholipid Antibodies

Contact Info

Product

Resources

About